DBP.B: SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus

About this update from Double Bond Pharmaceutical International Ab Class B

Double Bond Pharmaceutical reported lower revenues and continued losses in H1 2024, but advanced SI-053 development and secured new financing and partnerships, including a key deal with Vivo Biopharma. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Double Bond Pharmaceutical International Ab Class B